Castle Biosciences, Inc.

NASDAQ:CSTL

Medical - Diagnostics & Research

Healthcare
$33.38 +0.20%

+$0.04 today

Market cap
$1.03B
Beta
1.02
P/E (TTM)
-47.3
EPS (TTM)
-$0.43
52W Low $14.59High $44.28

Volume 0.38M

Average 0.37M

CSTL EBITDA Margin

EBITDA as a percentage of revenue.

Castle Biosciences, Inc.NASDAQ: CSTL

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -12.4%

EBITDA Margin was -12.4% in Q1 FY2026, down 16.4 pp from a year earlier. On a trailing-twelve-month basis it was -0.2%, down 12.0 pp year over year. Over 3 fiscal years it widened by 45.9 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 3.6% for the fiscal year ending Dec 2026, up from 3.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-12.4%-13.6 pp QoQ
Last fiscal yearDec 2025
3.3%-8.2 pp YoY
LTMMar 2026
-0.2%-12.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-16.4 pp-13.3 pp+3.0 pp
1 year-8.2 pp+0.3 pp+8.5 pp
3 years+45.9 pp+3.5 pp-42.3 pp
5 years+9.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
3.3%
Year-over-year change
-8.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CSTL compares with its peers on the latest reported figures

  • CSTL's LTM Mar 2026 EBITDA Margin of -0.2% is the 3rd highest of the 8 companies compared; the peer median is -19.1%.
  • Its year-over-year change of -12.0 pp is the 6th highest of 8, against a peer median of +5.8 pp.
  • Over three fiscal years its change of +45.9 pp compares with a peer median of +53.0 pp.
CSTL Competitors Peer median
EBITDA Margin for CSTL and competitors
Company Period LTM level YoY 3-year change
VCYTVeracyte, Inc.LTM Jun 202623.1% +13.6 pp+20.8 pp
NEONeoGenomics, Inc.LTM Jun 20261.7% +5.8 pp+10.8 pp
CSTLCastle Biosciences, Inc.LTM Mar 2026-0.2% -12.0 pp+45.9 pp
MDXHMDxHealth S.A.FY2025-13.0% +11.5 pp+85.2 pp
BDSXBiodesix, Inc.LTM Mar 2026-19.1% +17.8 pp+110.1 pp
GHGuardant Health, Inc.LTM Sep 2026-34.5% +4.7 pp+98.7 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-40.3% -32.6 pp-27.6 pp
PSNLPersonalis, Inc.LTM Mar 2026-132.6% -47.0 pp—
FRNMFreenome, Inc. Common stock—— ——
Peer median (excluding CSTL) -19.1%+5.8 pp+53.0 pp

Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue94.09M137.04M219.79M332.07M344.23M
Cost of Revenue15.82M32.01M44.98M60.21M71.03M
Gross Profit78.26M105.03M174.81M271.86M273.2M
Gross Margin83.2%76.6%79.5%81.9%79.4%
Research & Development29.65M44.9M53.62M52.04M51.85M
Selling, General & Admin86.74M143M180.15M200.05M229.32M
Operating Expenses118.34M177.89M242.78M263.19M316.01M
Depreciation & Amortization3.41M10.54M12.33M16M40.77M
EBITDA(36.6M)(58.34M)(45.02M)38.14M11.34M
EBITDA Margin-38.9%-42.6%-20.5%11.5%3.3%
Operating Income(40.08M)(72.86M)(67.98M)8.67M(42.81M)
Operating Margin-42.6%-53.2%-30.9%2.6%-12.4%
Interest Income68K3.97M10.62M12.92M11.77M
Interest Expense1K17K11K577K86K
Other Income / Expenses67K3.95M10.61M12.89M13.3M
Income Before Tax(40.01M)(68.9M)(57.37M)21.56M(29.51M)
Pre-Tax Margin-42.5%-50.3%-26.1%6.5%-8.6%
Income Tax Expense(8.72M)(1.77M)101K3.32M(5.36M)
Net Income(31.29M)(67.14M)(57.47M)18.25M(24.16M)
Net Margin-33.3%-49.0%-26.1%5.5%-7.0%
EPS (Basic)(1.24)(2.58)(2.14)0.66(0.83)
EPS (Diluted)(1.24)(2.58)(2.14)0.62(0.83)
Weighted Avg Shares25.14M26.05M26.8M27.78M28.99M
Weighted Avg Shares (Diluted)25.14M26.05M26.8M29.26M28.99M

Castle Biosciences, Inc.

NASDAQ:CSTL

Intrinsic Alpha fair value

Locked

Current Price

$33.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.